FDA Oncology Announcements

Anti-CD19-CD3 bispecific × Clear all

4 Announcements

FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

Drug: Blincyto (blinatumomab) · Anti-CD19-CD3 bispecific antibody
Conditions: LymphoidOther hematologic neoplasm

FDA granted accelerated approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia

Trial: BLAST
Drug: Blincyto (blinatumomab) · Anti-CD19-CD3 bispecific antibody
Conditions: LymphoidOther hematologic neoplasm

FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell

Drug: BLINCYTO (blinatumomab) · Anti-CD19-CD3 bispecific antibody
Condition: Lymphoid

Blinatumomab

Drug: BLINCYTO (blinatumomab) · Anti-CD19-CD3 bispecific antibody
Condition: Lymphoid